CRMD Elizabeth Hurlburt sells $1.6M worth of shares
Nov 19, 2024, 5:35 AM
-14.43%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
Elizabeth Hurlburt sold 140,027 shares of CRMD on 14 November at $11.18 per share, worth a total of $1.6M. They now own 45,397 CRMD shares, or a 76% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
